ERBB2 and breast carcinoma: T-BET expression in the intertumoral lymphoid tissue suggests a good prognosis with significantly improved recurrence-free survival in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer who underwent neoadjuvant trastuzumab-paclitaxel therapy [60, 61].